Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Retinal Disorders Therapy Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Retinal Disorders Therapy Industry
  • 1.7 COVID-19 Impact: Retinal Disorders Therapy Market Trends

    • 2 Global Retinal Disorders Therapy Quarterly Market Size Analysis

    • 2.1 Retinal Disorders Therapy Business Impact Assessment - COVID-19
      • 2.1.1 Global Retinal Disorders Therapy Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Retinal Disorders Therapy Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Retinal Disorders Therapy Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Retinal Disorders Therapy Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Retinal Disorders Therapy Market
    • 3.4 Key Players Retinal Disorders Therapy Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Retinal Disorders Therapy Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Age Related Macular Degeneration
      • 1.4.2 Diabetic Retinopathy
      • 1.4.3 Ocular Inflammatory Disease (Uveitis)
      • 1.4.4 Macular Hole
    • 4.2 By Type, Global Retinal Disorders Therapy Market Size, 2019-2021

    5 Impact of Covid-19 on Retinal Disorders Therapy Segments, By Application

    • 5.1 Overview
      • 5.5.1 Hospitals
      • 5.5.2 Clinics
      • 5.5.3 Others
    • 5.2 By Application, Global Retinal Disorders Therapy Market Size, 2019-2021
      • 5.2.1 By Application, Global Retinal Disorders Therapy Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 ALLERGAN
      • 7.1.1 ALLERGAN Business Overview
      • 7.1.2 ALLERGAN Retinal Disorders Therapy Quarterly Revenue, 2020
      • 7.1.3 ALLERGAN Retinal Disorders Therapy Product Introduction
      • 7.1.4 ALLERGAN Response to COVID-19 and Related Developments
    • 7.2 AbbVie
      • 7.2.1 AbbVie Business Overview
      • 7.2.2 AbbVie Retinal Disorders Therapy Quarterly Revenue, 2020
      • 7.2.3 AbbVie Retinal Disorders Therapy Product Introduction
      • 7.2.4 AbbVie Response to COVID-19 and Related Developments
    • 7.3 Alimera Sciences
      • 7.3.1 Alimera Sciences Business Overview
      • 7.3.2 Alimera Sciences Retinal Disorders Therapy Quarterly Revenue, 2020
      • 7.3.3 Alimera Sciences Retinal Disorders Therapy Product Introduction
      • 7.3.4 Alimera Sciences Response to COVID-19 and Related Developments
    • 7.4 Janssen Biotech
      • 7.4.1 Janssen Biotech Business Overview
      • 7.4.2 Janssen Biotech Retinal Disorders Therapy Quarterly Revenue, 2020
      • 7.4.3 Janssen Biotech Retinal Disorders Therapy Product Introduction
      • 7.4.4 Janssen Biotech Response to COVID-19 and Related Developments
    • 7.5 Swedish Orphan Biovitrum
      • 7.5.1 Swedish Orphan Biovitrum Business Overview
      • 7.5.2 Swedish Orphan Biovitrum Retinal Disorders Therapy Quarterly Revenue, 2020
      • 7.5.3 Swedish Orphan Biovitrum Retinal Disorders Therapy Product Introduction
      • 7.5.4 Swedish Orphan Biovitrum Response to COVID-19 and Related Developments
    • 7.6 Roche
      • 7.6.1 Roche Business Overview
      • 7.6.2 Roche Retinal Disorders Therapy Quarterly Revenue, 2020
      • 7.6.3 Roche Retinal Disorders Therapy Product Introduction
      • 7.6.4 Roche Response to COVID-19 and Related Developments
    • 7.7 Bristol-Myers Squibb
      • 7.7.1 Bristol-Myers Squibb Business Overview
      • 7.7.2 Bristol-Myers Squibb Retinal Disorders Therapy Quarterly Revenue, 2020
      • 7.7.3 Bristol-Myers Squibb Retinal Disorders Therapy Product Introduction
      • 7.7.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
    • 7.8 Genzyme
      • 7.8.1 Genzyme Business Overview
      • 7.8.2 Genzyme Retinal Disorders Therapy Quarterly Revenue, 2020
      • 7.8.3 Genzyme Retinal Disorders Therapy Product Introduction
      • 7.8.4 Genzyme Response to COVID-19 and Related Developments
    • 7.9 Genentech
      • 7.9.1 Genentech Business Overview
      • 7.9.2 Genentech Retinal Disorders Therapy Quarterly Revenue, 2020
      • 7.9.3 Genentech Retinal Disorders Therapy Product Introduction
      • 7.9.4 Genentech Response to COVID-19 and Related Developments
    • 7.10 OCULAR THERAPEUTIX
      • 7.10.1 OCULAR THERAPEUTIX Business Overview
      • 7.10.2 OCULAR THERAPEUTIX Retinal Disorders Therapy Quarterly Revenue, 2020
      • 7.10.3 OCULAR THERAPEUTIX Retinal Disorders Therapy Product Introduction
      • 7.10.4 OCULAR THERAPEUTIX Response to COVID-19 and Related Developments
    • 7.11 Bausch & Lomb
      • 7.11.1 Bausch & Lomb Business Overview
      • 7.11.2 Bausch & Lomb Retinal Disorders Therapy Quarterly Revenue, 2020
      • 7.11.3 Bausch & Lomb Retinal Disorders Therapy Product Introduction
      • 7.11.4 Bausch & Lomb Response to COVID-19 and Related Developments
    • 7.12 UCBCares
      • 7.12.1 UCBCares Business Overview
      • 7.12.2 UCBCares Retinal Disorders Therapy Quarterly Revenue, 2020
      • 7.12.3 UCBCares Retinal Disorders Therapy Product Introduction
      • 7.12.4 UCBCares Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Retinal Disorders Therapy, including the following market information:
      Global Retinal Disorders Therapy Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Retinal Disorders Therapy Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Retinal Disorders Therapy Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Retinal Disorders Therapy Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include ALLERGAN, AbbVie, Alimera Sciences, Janssen Biotech, Swedish Orphan Biovitrum, Roche, Bristol-Myers Squibb, Genzyme, Genentech, OCULAR THERAPEUTIX, Bausch & Lomb, UCBCares, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Age Related Macular Degeneration
      Diabetic Retinopathy
      Ocular Inflammatory Disease (Uveitis)
      Macular Hole

      Based on the Application:
      Hospitals
      Clinics
      Others

      Buy now